CA2889723A1 - Dna antibody constructs and method of using same - Google Patents

Dna antibody constructs and method of using same Download PDF

Info

Publication number
CA2889723A1
CA2889723A1 CA2889723A CA2889723A CA2889723A1 CA 2889723 A1 CA2889723 A1 CA 2889723A1 CA 2889723 A CA2889723 A CA 2889723A CA 2889723 A CA2889723 A CA 2889723A CA 2889723 A1 CA2889723 A1 CA 2889723A1
Authority
CA
Canada
Prior art keywords
acid sequence
nucleic acid
recombinant nucleic
antigen
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA2889723A
Other languages
English (en)
French (fr)
Inventor
David B. Weiner
Karuppiah Muthumani
Niranjan Sardesai
Seleeke FLINGAI
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Pennsylvania Penn
Inovio Pharmaceuticals Inc
Original Assignee
University of Pennsylvania Penn
Inovio Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Pennsylvania Penn, Inovio Pharmaceuticals Inc filed Critical University of Pennsylvania Penn
Publication of CA2889723A1 publication Critical patent/CA2889723A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1081—Togaviridae, e.g. flavivirus, rubella virus, hog cholera virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/33—Antibodies; T-cell engagers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1036—Retroviridae, e.g. leukemia viruses
    • C07K16/1045—Lentiviridae, e.g. HIV, FIV, SIV
    • C07K16/1063—Lentiviridae, e.g. HIV, FIV, SIV env, e.g. gp41, gp110/120, gp160, V3, PND, CD4 binding site
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M37/00—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
    • A61M2037/0007—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin having means for enhancing the permeation of substances through the epidermis, e.g. using suction or depression, electric or magnetic fields, sound waves or chemical agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • AIDS & HIV (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CA2889723A 2012-12-13 2013-12-13 Dna antibody constructs and method of using same Pending CA2889723A1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201261737094P 2012-12-13 2012-12-13
US61/737,094 2012-12-13
US201361881376P 2013-09-23 2013-09-23
US61/881,376 2013-09-23
US201361896646P 2013-10-28 2013-10-28
US61/896,646 2013-10-28
PCT/US2013/075137 WO2014093894A2 (en) 2012-12-13 2013-12-13 Dna antibody constructs and method of using same

Publications (1)

Publication Number Publication Date
CA2889723A1 true CA2889723A1 (en) 2014-06-19

Family

ID=50935092

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2889723A Pending CA2889723A1 (en) 2012-12-13 2013-12-13 Dna antibody constructs and method of using same

Country Status (15)

Country Link
US (4) US9994629B2 (OSRAM)
EP (1) EP2931318A4 (OSRAM)
JP (6) JP6898060B2 (OSRAM)
KR (4) KR20230156146A (OSRAM)
CN (1) CN104853782A (OSRAM)
AU (7) AU2013358944B2 (OSRAM)
BR (2) BR112015013700A8 (OSRAM)
CA (1) CA2889723A1 (OSRAM)
EA (1) EA201591131A1 (OSRAM)
HK (1) HK1213481A1 (OSRAM)
MX (4) MX2015007575A (OSRAM)
MY (1) MY175708A (OSRAM)
SG (1) SG10202002718RA (OSRAM)
WO (1) WO2014093894A2 (OSRAM)
ZA (1) ZA201503583B (OSRAM)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20230156146A (ko) * 2012-12-13 2023-11-13 더 트러스티스 오브 더 유니버시티 오브 펜실베니아 Ｄｎａ 항체 작제물 및 그 이용 방법
EP3080159A4 (en) * 2013-12-13 2017-08-02 The Trustees Of The University Of Pennsylvania Dna antibody constructs and method of using same
CA2962799A1 (en) * 2014-10-01 2016-04-07 The Trustees Of The University Of Pennsylvania Vaccines having an antigen and interleukin-21 as an adjuvant
EP3226892A4 (en) * 2014-12-01 2018-07-18 The Trustees Of The University Of Pennsylvania Dna antibody constructs and method of using same
NZ781602A (en) 2015-10-25 2025-07-25 Sanofi Sa Trispecific and/or trivalent binding proteins for prevention or treatment of hiv infection
US20180363000A1 (en) * 2015-12-14 2018-12-20 The Trustees Of The University Of Pennsylvania Aav-anti pcsk9 antibody constructs and uses thereof
JP2019509350A (ja) * 2016-03-21 2019-04-04 ビー．ウェイナー デイビッド Ｄｎａ抗体構築物及びその使用方法
EP4257193B1 (en) 2016-04-13 2025-12-31 Sanofi TRISPECIFIC AND/OR TRIVALENT LINKING PROTEINS
KR102375327B1 (ko) * 2016-05-05 2022-03-17 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 관문 분자를 표적으로 하는 dna 단클론성 항체
KR20190025826A (ko) 2016-05-05 2019-03-12 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 슈도모나스 에루지노사에 대해 사용하기 위한 dna 항체 작제물
KR20220035288A (ko) * 2016-05-05 2022-03-21 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 인플루엔자 바이러스를 표적으로 하는 dna 단일 클론 항체
SG11201809786TA (en) * 2016-05-05 2018-12-28 Univ Pennsylvania Dna monoclonal antibodies targeting il-6 and cd126
CA3037486A1 (en) 2016-09-19 2018-03-22 The Trustees Of The University Of Pennsylvania Combination of novel vaccines against zika virus and dna antibody constructs for use against zika virus
US11286295B2 (en) 2016-10-20 2022-03-29 Sanofi Anti-CHIKV monoclonal antibodies directed against the E2 structural protein
CN110167584B (zh) * 2016-11-07 2024-06-07 威斯塔解剖学和生物学研究所 用于针对莱姆病的dna抗体构建体
US11370830B2 (en) 2017-04-07 2022-06-28 The Rockefeller University Neutralizing antibodies that bind to the zika virus domain III envelope region
TWI673285B (zh) * 2017-05-22 2019-10-01 國立成功大學 抗－登革熱病毒抗體、包含該抗體之藥學組合物及其用途
US11230592B2 (en) * 2017-09-27 2022-01-25 The Wistar Institute Of Anatomy And Biology DNA antibody constructs for use against middle east respiratory syndrome coronavirus
WO2019152602A1 (en) * 2018-01-31 2019-08-08 The Wistar Institute Of Anatomy And Biology Structurally modified flavivirus dmabs
US11613576B2 (en) 2019-04-09 2023-03-28 Sanofi Trispecific binding proteins, methods, and uses thereof
AU2020323601A1 (en) * 2019-07-31 2022-03-03 The Wistar Institute Of Anatomy And Biology Multivalent DNA antibody constructs and use thereof
GB2606844B (en) 2019-09-18 2025-08-06 Aldevron Llc Synthetic DNA vectors and methods of use
SE544000C2 (en) * 2020-03-17 2021-10-26 Xbrane Biopharma Ab Novel combination of tis sequence, signal peptide sequence and nucleic acid sequence encoding a recombinant protein
SE544001C2 (en) * 2020-03-17 2021-10-26 Xbrane Biopharma Ab Novel combination of tis sequences, signal peptide sequences and nucleic acid sequences encoding heavy and light chains of an antibody
WO2021188906A1 (en) * 2020-03-19 2021-09-23 Nature's Toolbox, Inc. Novel mrna-based covid-19 multi-valent vaccine and methods of scaled production of the same
BR112022022719A2 (pt) * 2020-05-14 2023-02-14 Inovio Pharmaceuticals Inc Vacinas para papilomatose respiratória recorrente e métodos de usar a mesma
JP2023552206A (ja) * 2020-12-02 2023-12-14 トーマス・ジェファーソン・ユニバーシティー デスモグレイン２指向性キメラ抗原受容体（ｃａｒ）コンストラクトと利用法

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI46572C (fi) * 1972-04-07 1973-04-10 Stroemberg Oy Ab Jännitemuuntaja.
US7276488B2 (en) 1997-06-04 2007-10-02 Oxford Biomedica (Uk) Limited Vector system
US20030039635A1 (en) 1998-09-30 2003-02-27 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
CN1334343A (zh) * 2000-07-14 2002-02-06 中国医学科学院肿瘤医院肿瘤研究所 抑制肿瘤生长的新抗体、其衍生物及其应用
US20070037165A1 (en) 2000-09-08 2007-02-15 Applera Corporation Polymorphisms in known genes associated with human disease, methods of detection and uses thereof
WO2004013278A2 (en) * 2002-08-02 2004-02-12 Yuhan Corporation Expression vectors
CA2526120A1 (en) * 2003-06-03 2005-02-24 Cell Genesys, Inc. Compositions and methods for enhanced expression of recombinant polypeptides from a single vector using a peptide cleavage site
CN1480215A (zh) 2003-07-07 2004-03-10 叶新新 Sars病毒抗原抗体复合疫苗及实验动物模型与方法
BRPI0520902B1 (pt) * 2004-05-28 2021-11-30 Agensys, Inc Anticorpo monoclonal ou fragmento de ligação ao antígeno do mesmo que se liga a proteínas psca para diagnóstico de câncer, método para produção dos mesmos, hibridoma, polinucleotídeo, vetor, composição, ensaio para detectar a presença de uma proteína psca e método de detecção de uma proteína psca
PL1753871T3 (pl) 2004-05-28 2016-01-29 Agensys Inc Przeciwciała i powiązane cząsteczki, które wiążą się z antygenem komórek macierzystych prostaty (PSCA)
CA2573656A1 (en) * 2004-07-13 2006-02-16 Cell Genesys, Inc. Aav vector compositions and methods for enhanced expression of immunoglobulins using the same
KR20190126461A (ko) 2004-07-22 2019-11-11 제넨테크, 인크. Ｈｅｒ２ 항체 조성물
JO3000B1 (ar) * 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
CA2598454C (en) 2005-02-18 2013-04-09 Medarex, Inc. Monoclonal antibodies against prostate specific membrane antigen (psma) lacking in fucosyl residues
US20060216722A1 (en) 2005-03-25 2006-09-28 Christer Betsholtz Glomerular expression profiling
CA2615983A1 (en) 2005-07-21 2007-02-01 Abbott Laboratories Multiple gene expression including sorf constructs and methods with polyproteins, pro-proteins, and proteolysis
WO2009026274A1 (en) 2007-08-22 2009-02-26 Medarex, Inc. Site-specific attachment of drugs or other agents to engineered antibodies with c-terminal extensions
CA2598966A1 (en) 2007-09-07 2009-03-07 Institut Pasteur Anti-chikungunya monoclonal antibodies and uses thereof
JP2009171880A (ja) 2008-01-23 2009-08-06 Yokohama City Univ アルツハイマー病における次世代遺伝子治療法・免疫治療法の開発
KR101633520B1 (ko) 2008-03-14 2016-06-24 트랜스진 에스.에이. Ｃｓｆ－１ｒ에 대한 항체
EP2274442B1 (en) 2008-04-04 2016-06-29 The Trustees Of The University Of Pennsylvania Consensus sequences of chikungunya viral proteins, nucleic acid molecules encoding the same, and compositions and methods for using the same
AU2009305113B2 (en) 2008-10-13 2015-07-16 Institute For Research In Biomedicine Dengue virus neutralizing antibodies and uses thereof
SG177560A1 (en) * 2009-07-06 2012-03-29 Hoffmann La Roche Bi-specific digoxigenin binding antibodies
EP2453917B1 (en) 2009-07-13 2015-07-22 Bharat Biotech International Limited A composition useful as rotavirus vaccine and a method therefor.
US20110045534A1 (en) 2009-08-20 2011-02-24 Cell Signaling Technology, Inc. Nucleic Acid Cassette For Producing Recombinant Antibodies
US9175070B2 (en) * 2009-09-25 2015-11-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Neutralizing antibodies to HIV-1 and their use
JP2013508287A (ja) * 2009-10-14 2013-03-07 ヤンセン バイオテツク，インコーポレーテツド 抗体を親和性成熟する方法
US8298820B2 (en) * 2010-01-26 2012-10-30 The Trustees Of The University Of Pennsylvania Influenza nucleic acid molecules and vaccines made therefrom
NZ703035A (en) 2010-07-09 2016-06-24 Crucell Holland Bv Anti-human respiratory syncytial virus (rsv) antibodies and methods of use
CN103097413A (zh) * 2010-07-09 2013-05-08 Jv生物公司 脂质缀合抗体
US8637035B2 (en) 2010-07-16 2014-01-28 Academia Sinica Anti-dengue virus antibodies
KR101939150B1 (ko) 2010-11-12 2019-01-17 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 공통 전립선 항원, 이것을 암호화하는 핵산 분자, 그리고 이것을 포함하는 백신 및 용도
AU2012212264B2 (en) 2011-01-31 2016-01-28 The Trustees Of The University Of Pennsylvania Nucleic acid molecules encoding novel herpes antigens, vaccine comprising the same, and methods of use thereof
WO2012106578A1 (en) 2011-02-04 2012-08-09 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services HIV NEUTRALIZING ANTIBODIES HAVING MUTATIONS IN CONSTANT DOMAIN (Fc)
EP2678433B1 (en) * 2011-02-22 2017-05-03 California Institute of Technology Delivery of proteins using adeno-associated virus (aav) vectors
CN102199218A (zh) * 2011-04-29 2011-09-28 中国人民解放军军事医学科学院基础医学研究所 一种抗Her2抗体-白细胞介素2融合蛋白及其用途
WO2013177533A1 (en) 2012-05-25 2013-11-28 California Institute Of Technology Expression of secreted and cell-surface polypeptides
JP7078350B2 (ja) * 2013-10-28 2022-05-31 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア Ｄｎａ抗体構築物及びその使用方法
KR20230156146A (ko) 2012-12-13 2023-11-13 더 트러스티스 오브 더 유니버시티 오브 펜실베니아 Ｄｎａ 항체 작제물 및 그 이용 방법
CN104812401B (zh) 2012-12-13 2017-10-13 宾夕法尼亚大学理事会 Wt1疫苗
EP2934577A1 (en) 2012-12-19 2015-10-28 Adimab, LLC Multivalent antibody analogs, and methods of their preparation and use
EP3080159A4 (en) 2013-12-13 2017-08-02 The Trustees Of The University Of Pennsylvania Dna antibody constructs and method of using same

Also Published As

Publication number Publication date
MY175708A (en) 2020-07-06
AU2018202997A1 (en) 2018-05-17
AU2019202343A1 (en) 2019-05-02
BR112015013700A2 (pt) 2017-11-14
KR20230156146A (ko) 2023-11-13
CN104853782A (zh) 2015-08-19
KR20160093724A (ko) 2016-08-08
MX2015007575A (es) 2016-03-15
MX2021015971A (es) 2022-02-10
JP2016501535A (ja) 2016-01-21
WO2014093894A3 (en) 2014-07-31
EP2931318A2 (en) 2015-10-21
EA201591131A1 (ru) 2015-12-30
ZA201503583B (en) 2019-12-18
JP6898060B2 (ja) 2021-07-07
AU2020201853B2 (en) 2022-07-28
JP2023080085A (ja) 2023-06-08
KR20210088741A (ko) 2021-07-14
BR112016013493B1 (pt) 2024-02-27
KR20150093834A (ko) 2015-08-18
KR102454610B1 (ko) 2022-10-13
AU2020201853A1 (en) 2020-04-02
JP2023138998A (ja) 2023-10-03
US20150284448A1 (en) 2015-10-08
MX2016007722A (es) 2017-03-08
AU2013358944B2 (en) 2016-08-18
AU2021203643A1 (en) 2021-07-01
HK1213481A1 (zh) 2016-07-08
AU2013358944A1 (en) 2015-05-28
JP2019115355A (ja) 2019-07-18
WO2014093894A2 (en) 2014-06-19
BR112016013493A2 (en) 2018-03-27
MX388911B (es) 2025-03-20
US9994629B2 (en) 2018-06-12
JP2021087433A (ja) 2021-06-10
AU2014361811A1 (en) 2016-07-21
SG10202002718RA (en) 2020-05-28
EP2931318A4 (en) 2016-07-20
JP2020108381A (ja) 2020-07-16
AU2016259451A1 (en) 2016-12-08
US11208470B2 (en) 2021-12-28
US20180346554A1 (en) 2018-12-06
MX2022016002A (es) 2023-02-02
AU2019202343B2 (en) 2021-07-01
AU2014361811B2 (en) 2018-02-01
US20190085058A1 (en) 2019-03-21
US20220112273A1 (en) 2022-04-14
BR112015013700A8 (pt) 2020-02-18

Similar Documents

Publication Publication Date Title
AU2019202343B2 (en) DNA antibody constructs and method of using same
US20230023093A1 (en) Dna antibody constructs and method of using same
US10087240B2 (en) DNA antibody constructs and method of using same
EA042816B1 (ru) Днк-конструкции антитела и способ их применения

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20181206

EEER Examination request

Effective date: 20181206

EEER Examination request

Effective date: 20181206

EEER Examination request

Effective date: 20181206

EEER Examination request

Effective date: 20181206

EEER Examination request

Effective date: 20181206

EEER Examination request

Effective date: 20181206

EEER Examination request

Effective date: 20181206

EEER Examination request

Effective date: 20181206

EEER Examination request

Effective date: 20181206